| __timestamp | ACADIA Pharmaceuticals Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 11606000000 |
| Thursday, January 1, 2015 | 90804000 | 10313000000 |
| Friday, January 1, 2016 | 186456000 | 9762000000 |
| Sunday, January 1, 2017 | 255062000 | 9830000000 |
| Monday, January 1, 2018 | 265758000 | 10102000000 |
| Tuesday, January 1, 2019 | 325638000 | 10615000000 |
| Wednesday, January 1, 2020 | 388661000 | 8955000000 |
| Friday, January 1, 2021 | 396028000 | 9634000000 |
| Saturday, January 1, 2022 | 369090000 | 10042000000 |
| Sunday, January 1, 2023 | 402466000 | 10504000000 |
Unleashing insights
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Merck & Co., Inc. and ACADIA Pharmaceuticals Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Merck's SG&A expenses have shown a slight decline, averaging around $10 billion annually, with a notable dip in 2020. This suggests a strategic focus on cost efficiency, possibly driven by operational streamlining.
Conversely, ACADIA Pharmaceuticals has seen a steady increase in SG&A expenses, growing from approximately $33 million in 2014 to over $400 million in 2023. This 12-fold increase reflects ACADIA's aggressive expansion and investment in marketing and administrative capabilities. As these companies continue to evolve, their SG&A strategies will be pivotal in shaping their financial futures.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
R&D Spending Showdown: Merck & Co., Inc. vs ACADIA Pharmaceuticals Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and ACADIA Pharmaceuticals Inc.
CymaBay Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ACADIA Pharmaceuticals Inc.
Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Soleno Therapeutics, Inc. Trends and Insights